Integrating Public Health Concerns into Patent Legislation in Developing Countries
(2000; 140 pages) [French] [Spanish] View the PDF document
Table of Contents
View the documentTHE SOUTH CENTRE
View the documentFOREWORD
View the documentACKNOWLEDGEMENTS
View the documentGLOSSARY*
Open this folder and view contentsI. INTRODUCTION
Open this folder and view contentsII. PATENTABLE SUBJECT MATTER
Open this folder and view contentsIII. SCOPE OF CLAIMS
Open this folder and view contentsIV. PATENTABILITY REQUIREMENTS
Close this folderV. SPECIAL CASES IN PHARMACEUTICALS
View the documentV.1 Selection Patents
View the documentV.2 Prior Public Availability
View the documentV.3 Polymorphism
View the documentV.4 Analogy processes
View the documentV.5 Compositions
View the documentV.6 Optical Isomers
View the documentV.7 Active Metabolites
View the documentV.8 Prodrugs
Open this folder and view contentsVI. DISCLOSURE
Open this folder and view contentsVII. EXCEPTIONS TO EXCLUSIVE RIGHTS
Open this folder and view contentsVIII. EXAMINATION AND OBSERVATION PROCEDURES
Open this folder and view contentsIX. CLAIMS INTERPRETATION
Open this folder and view contentsX. COMPULSORY LICENSING
View the documentXI. FINAL REMARKS
View the documentREFERENCES
View the documentBACK COVER
 

V.1 Selection Patents

A “selection patent” is a patent under which a single element or a small segment within a large known group is “selected” and independently claimed, based on a particular feature not mentioned in the large group96. If the large group of elements is already patented97, the patent owner may use the selection patent to extend the term of protection beyond the expiration of the original patent, at least for the selected subset. While accepted in some jurisdictions when the selected elements possess a surprising advantage, selection patents have been denied when the supposed advantage is a property shared by all or nearly all of the large group. Germany has refused selection inventions by holding that disclosure of even a large group of elements is fully equivalent, for the purposes of inventive step, to the disclosure of each compound within the group98.

96 A “selection invention” may take place, for instance, when a range of products characterized as having N carbon atoms has been patented, and, later on, a patent on a specific range (e.g. C1-C4) is claimed. Substantial differences exist in the treatment of these patents, including between the European Patent Office (EPO) and some national offices in Europe.

97 Often broad (“generic”) patent claims are admitted, covering a large number (sometimes thousands) of possible compounds.

98 See, e.g., Grubb, 1999, p. 197-199.

An important policy issue is, therefore, to decide whether and under which conditions selection patents should be admitted. The TRIPs Agreement leaves broad discretion to national laws and practices in this area.

to previous section
to next section
 
 
The WHO Essential Medicines and Health Products Information Portal was designed and is maintained by Human Info NGO. Last updated: March 20, 2014